troglitazone has been researched along with Liver Cirrhosis in 5 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 68-year-old woman, with type 2 diabetes mellitus, hypercholesterolemia, and prior long-term simvastatin therapy, self-resumed troglitazone after running out of metformin." | 7.71 | Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. ( Caldwell, SH; Hespenheide, EE; von Borstel, RW, 2001) |
| "Troglitazone is a thiazolidinedione antidiabetic agent with insulin-sensitizing activities that was withdrawn from the market in 2000 due to its association with idiosyncratic hepatotoxicity." | 5.33 | Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. ( Kaneko, S; Katoh, K; Maniratanachote, R; Nakajima, M; Sawazaki, T; Shibata, A; Tokudome, S; Wakasugi, T; Yamamori, I; Yokoi, T, 2005) |
| "A 68-year-old woman, with type 2 diabetes mellitus, hypercholesterolemia, and prior long-term simvastatin therapy, self-resumed troglitazone after running out of metformin." | 3.71 | Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. ( Caldwell, SH; Hespenheide, EE; von Borstel, RW, 2001) |
| "Troglitazone is a thiazolidinedione antidiabetic agent with insulin-sensitizing activities that was withdrawn from the market in 2000 due to its association with idiosyncratic hepatotoxicity." | 1.33 | Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. ( Kaneko, S; Katoh, K; Maniratanachote, R; Nakajima, M; Sawazaki, T; Shibata, A; Tokudome, S; Wakasugi, T; Yamamori, I; Yokoi, T, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, WM | 1 |
| Maniratanachote, R | 1 |
| Shibata, A | 1 |
| Kaneko, S | 1 |
| Yamamori, I | 1 |
| Wakasugi, T | 1 |
| Sawazaki, T | 1 |
| Katoh, K | 1 |
| Tokudome, S | 1 |
| Nakajima, M | 1 |
| Yokoi, T | 1 |
| Marra, F | 2 |
| Efsen, E | 1 |
| Romanelli, RG | 1 |
| Caligiuri, A | 1 |
| Pastacaldi, S | 2 |
| Batignani, G | 1 |
| Bonacchi, A | 1 |
| Caporale, R | 1 |
| Laffi, G | 1 |
| Pinzani, M | 1 |
| Gentilini, P | 1 |
| Caldwell, SH | 1 |
| Hespenheide, EE | 1 |
| von Borstel, RW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity[NCT02353455] | 300 participants (Anticipated) | Observational | 2013-03-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for troglitazone and Liver Cirrhosis
| Article | Year |
|---|---|
Drug-induced hepatotoxicity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzophenones; Bromobenzenes; Chemical and Drug Induced Liv | 2003 |
[Thiazolidinediones and PPARgamma system in repair of liver damage].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antioxidants; Arteriosclerosis; Chro | 2002 |
3 other studies available for troglitazone and Liver Cirrhosis
| Article | Year |
|---|---|
Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction.
Topics: Aged; Alanine Transaminase; Autoantibodies; Chemical and Drug Induced Liver Injury; Chromans; Diabet | 2005 |
Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells.
Topics: Antineoplastic Agents; Biological Transport; Cell Division; Cell Movement; Cell Survival; Cells, Cul | 2000 |
Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin.
Topics: Aged; Anticholesteremic Agents; Antioxidants; Chemical and Drug Induced Liver Injury; Chromans; Diab | 2001 |